Antonia Valenzuela

Oct 21, 2024 | ard.bmj.com | Sofia Ferreira Azevedo |Antonia Valenzuela |Cristian Alejandro Benitez |David Isenberg

Delayed-start arms, such as in the phase 2 MYOJAK (NCT04208464, testing baricitinib, a JAK 1/2 inhibitor) and ARTEMIS (NCT01315938, testing abatacept, a CTLA-4 analogue that blocks the costimulatory signal mediated by the CD28-CD80/86 pathway) IIM clinical trials, randomise subjects to a briefer placebo-controlled phase either at the beginning or at the end of the trial. All subjects receive treatment which incentivises patient participation.

Oct 21, 2024 | ard.bmj.com | Sofia Ferreira Azevedo |Antonia Valenzuela |Cristian Alejandro Benitez |David Isenberg

Delayed-start arms, such as in the phase 2 MYOJAK (NCT04208464, testing baricitinib, a JAK 1/2 inhibitor) and ARTEMIS (NCT01315938, testing abatacept, a CTLA-4 analogue that blocks the costimulatory signal mediated by the CD28-CD80/86 pathway) IIM clinical trials, randomise subjects to a briefer placebo-controlled phase either at the beginning or at the end of the trial. All subjects receive treatment which incentivises patient participation.

Mar 28, 2024 | ard.bmj.com | Sofia Ferreira Azevedo |Antonia Valenzuela |Cristian Alejandro Benitez |David Isenberg

Autoimmune DiseasesDermatomyositisOutcome Assessment, Health CarePatient Reported Outcome MeasuresPolymyositisWe read the viewpoint titled ‘current myositis clinical trials and tribulations’ with great interest.1 We congratulate the authors for addressing critical patient-centred and science-forward concerns in idiopathic inflammatory myopathies (IIMs) clinical trials.

Mar 28, 2024 | ard.bmj.com | Sofia Ferreira Azevedo |Antonia Valenzuela |Cristian Alejandro Benitez |David Isenberg

Autoimmune DiseasesDermatomyositisOutcome Assessment, Health CarePatient Reported Outcome MeasuresPolymyositisWe read the viewpoint titled ‘current myositis clinical trials and tribulations’ with great interest.1 We congratulate the authors for addressing critical patient-centred and science-forward concerns in idiopathic inflammatory myopathies (IIMs) clinical trials.

Mar 28, 2024 | ard.bmj.com | Antonia Valenzuela |David Isenberg |Sofia Ferreira Azevedo |Cristian Alejandro Benitez

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.